Elevated CYP24A1 levels in colorectal adenomas and carcinomas correlate with proliferation markers and poor prognosis, and contribute to resistance to calcitriol-based therapies by promoting hormone inactivation. This evidence concerns the gene CYP24A1 and carcinoma.